SpringerLink
Log in

Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson’s disease

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

Clinical trials in Parkinson’s disease commonly employ outcome measures of disability and quality of life. Responsiveness of these outcomes measures to symptomatic decline versus improvement has not been studied. We wanted to study the responsiveness of Schwab & England Activities of Daily Living Scale (SE) and Short Form-12 (SF-12) to symptomatic decline versus improvement in Parkinson’s disease over a 4-year period among a naturalistic cohort of patients.

Methods

Parkinson’s disease patients (N = 228, disease duration 6.1 years) were followed for 4 years with assessments of disease severity, Unified Parkinson’s Disease Rating Scale (UPDRS), health-related quality of life (SF-12 physical/mental health), and disability (SE). The sample was subdivided into those who declined (N = 118) or improved (N = 102) on total-UPDRS. Responsiveness was assessed with Cohen’s effect size and standardized response mean.

Results

At baseline, patients who improved over 4 years had greater disease severity and worse quality of life than decliners (p < .05). Decliners had a 13.5-point worsening on total-UPDRS, 26.3–39.8; p < .001) associated with concomitant decline on the SF-12 (physical health 42.9–39.2, mental health 50.0–46.6; both p < .001) and the SE (85–74 %; p < .001). Improvers had a 13.0-point improvement on total-UPDRS (39.8–26.8; p < .001) associated with minimal change on the SF-12 (physical health 40.8–39.5, mental health 47.1–46.3) and SE (79–79 %). Based on effect size, the rank order of responsiveness of measures for decliners from high to low was SE (−0.78), Short Form-12 mental health (−0.45), and SF-12 physical health (−0.34). Rank order of responsiveness for improvers was Short Form-12 physical health (−0.11), SF-12 mental health (−0.10), and SE (−0.03).

Conclusions

Among decliners, measures of disability and quality of life were moderate to highly responsive to change in disease severity. Among improvers, both disability and quality of life were poorly responsive despite UPDRS improvement of comparable magnitude.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shulman, L. M. (2010). Understanding disability in Parkinson’s disease. Movement Disorders, 25(S1), S131–S135. doi:10.1002/mds.22789.

    Article  PubMed  Google Scholar 

  2. Cella, D. F. (1995). Measuring quality of life in palliative care. Seminars in Oncology, 22(2 Suppl 3), 73–81.

    CAS  PubMed  Google Scholar 

  3. Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Herlofson, K., & Alves, G. (2008). Predictors and course of health-related quality of life in Parkinson’s disease. Movement Disorders, 23(10), 1420–1427. doi:10.1002/mds.22121.

    Article  PubMed  Google Scholar 

  4. Karlsen, K. H., Tandberg, E., Arsland, D., & Larsen, J. P. (2000). Health related quality of life in Parkinson’s disease: A prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 69(5), 584–589.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hely, M. A., Morris, J. G. L., Traficante, R., Reid, W. G. J., O’Sullivan, D. J., & Williamson, P. M. (1999). The Sydney multicentre study of Parkinson’s disease: Progression and mortality at 10 years. Journal of Neurology, Neurosurgery and Psychiatry, 67(3), 300–307. doi:10.1136/jnnp.67.3.300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005). Sydney Multicenter Study of Parkinson’s disease: Non-L-dopa-responsive problems dominate at 15 years. Movement Disorders, 20(2), 190–199. doi:10.1002/mds.20324.

    Article  PubMed  Google Scholar 

  7. Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008). The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Movement Disorders, 23(6), 837–844. doi:10.1002/mds.21956.

    Article  PubMed  Google Scholar 

  8. Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2007). Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain, 130(7), 1787–1798. doi:10.1093/brain/awm111.

    Article  CAS  PubMed  Google Scholar 

  9. Vu, T. C., Nutt, J. G., & Holford, N. H. G. (2012). Progression of motor and nonmotor features of Parkinson’s disease and their response to treatment. British Journal of Clinical Pharmacology, 74(2), 267–283. doi:10.1111/j.1365-2125.2012.04192.x.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Evans, J. R., Mason, S. L., Williams-Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2011). The natural history of treated Parkinson’s disease in an incident, community based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 82(10), 1112–1118. doi:10.1136/jnnp.2011.240366.

    Article  PubMed  Google Scholar 

  11. Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.

    Article  PubMed  Google Scholar 

  12. Hauser, R. A., Hsu, A., Kell, S., Espay, A. J., Sethi, K., Stacy, M., et al. (2013). Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: A phase 3 randomised, double-blind trial. The Lancet Neurology, 12(4), 346–356. doi:10.1016/S1474-4422(13)70025-5.

    Article  CAS  PubMed  Google Scholar 

  13. Stocchi, F., Hsu, A., Khanna, S., Ellenbogen, A., Mahler, A., Liang, G., et al. (2014). Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism and Related Disorders, 20(12), 1335–1340. doi:10.1016/j.parkreldis.2014.08.004.

    Article  PubMed  Google Scholar 

  14. Fahn, S., Elton, R., & Members of the UPDRS Development Committee. (1987). Unified Parkinson’s Disease Rating Scale. In S. Fahn, C. D. Marsden, D. B. Calne & M. Goldstein (Eds.), Recent developments in Parkinson’s disease (Vol. 2, pp. 153–164). Forest Park, NJ: Macmillan Health Care Information.

  15. Martínez-Martín, P., Gil-Nagel, A., Gracia, L. M., Gómez, J. B., Martínez-Sarriés, J., & Bermejo, F. (1994). Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Movement Disorders, 9(1), 76–83. doi:10.1002/mds.870090112.

    Article  PubMed  Google Scholar 

  16. Schwab, R. S., & England, A. C. (1969). Projection technique for evaluating surgery in Parkinson’s disease. In F. J. Gillingham & I. M. L. Danoldson (Eds.), Third symposium on Parkinson’s disease (pp. 152–157). Edinburgh: Churchill Livingstone.

    Google Scholar 

  17. Ware, J., Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.

    Article  PubMed  Google Scholar 

  18. Pelle, A. J., Kupper, N., Mols, F., & de Jonge, P. (2013). What is the use? Application of the short form (SF) questionnaires for the evaluation of treatment effects. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 22(6), 1225–1230. doi:10.1007/s11136-012-0266-8.

    Article  Google Scholar 

  19. Martinez-Martin, P., Jeukens-Visser, M., Lyons, K. E., Rodriguez-Blazquez, C., Selai, C., Siderowf, A., et al. (2011). Health-related quality-of-life scales in Parkinson’s disease: Critique and recommendations. Movement Disorders, 26(13), 2371–2380. doi:10.1002/mds.23834.

    Article  PubMed  Google Scholar 

  20. Martinez-Martin, P., Prieto, L., & Forjaz, M. J. (2006). Longitudinal metric properties of disability rating scales for Parkinson’s disease. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 9(6), 386–393. doi:10.1111/j.1524-4733.2006.00131.x.

    Article  Google Scholar 

  21. Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: Onset, progression and mortality. Neurology, 17(5), 427–442.

    Article  CAS  PubMed  Google Scholar 

  22. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.

    Article  CAS  PubMed  Google Scholar 

  23. Pahwa, R., Lyons, K. E., Hauser, R. A., Fahn, S., Jankovic, J., Pourcher, E., et al. (2014). Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Related Disorders, 20(2), 142–148. doi:10.1016/j.parkreldis.2013.08.017.

    Article  PubMed  Google Scholar 

  24. Linn, B. S., Linn, M. W., & Gurel, L. (1968). Cumulative illness rating scale. Journal of the American Geriatrics Society, 16(5), 622–626.

    Article  CAS  PubMed  Google Scholar 

  25. Cohen, J. (1998). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: Lawrence Earlbaum Associates.

    Google Scholar 

  26. Liang, M. H. (1995). Evaluating measurement responsiveness. The Journal of Rheumatology, 22(6), 1191–1192.

    CAS  PubMed  Google Scholar 

  27. Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., & Weiner, W. J. (2010). The clinically important difference on the unified Parkinson’s disease rating scale. Archives of Neurology, 67(1), 64–70. doi:10.1001/archneurol.2009.295.

    Article  PubMed  Google Scholar 

  28. Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006). Minimal clinically important change on the unified Parkinson’s disease rating scale. Movement Disorders, 21(8), 1200–1207. doi:10.1002/mds.20914.

    Article  PubMed  Google Scholar 

  29. Hauser, R. A., Gordon, M. F., Mizuno, Y., Poewe, W., Barone, P., Schapira, A. H., et al. (2014). Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinson’s Disease, 2014(2014), e467131. doi:10.1155/2014/467131.

    Google Scholar 

  30. Merola, A., Zibetti, M., Angrisano, S., Rizzi, L., Ricchi, V., Artusi, C. A., et al. (2011). Parkinson’s disease progression at 30 years: A study of subthalamic deep brain-stimulated patients. Brain, 134(Pt 7), 2074–2084. doi:10.1093/brain/awr121.

    Article  PubMed  Google Scholar 

  31. Zibetti, M., Merola, A., Rizzi, L., Ricchi, V., Angrisano, S., Azzaro, C., et al. (2011). Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson’s disease. Movement Disorders, 26(13), 2327–2334. doi:10.1002/mds.23903.

    Article  PubMed  Google Scholar 

  32. Duarte, J., García Olmos, L. M., Mendoza, A., & Clavería, L. E. (2013). The natural history of Parkinson’s disease in the province of Segovia: Mortality in a longitudinal study (20-year follow-up). Acta Neurologica Scandinavica, 127(5), 295–300. doi:10.1111/ane.12003.

    Article  CAS  PubMed  Google Scholar 

  33. Ringash, J., O’Sullivan, B., Bezjak, A., & Redelmeier, D. A. (2007). Interpreting clinically significant changes in patient-reported outcomes. Cancer, 110(1), 196–202. doi:10.1002/cncr.22799.

    Article  PubMed  Google Scholar 

  34. Cella, D., Hahn, E. A., & Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Quality of Life Research, 11(3), 207–221.

    Article  PubMed  Google Scholar 

  35. Sprangers, M. A., & Schwartz, C. E. (1999). Integrating response shift into health-related quality of life research: A theoretical model. Social Science and Medicine (1982), 48(11), 1507–1515.

    Article  CAS  Google Scholar 

  36. Tubach, F., Dougados, M., Falissard, B., Baron, G., Logeart, I., & Ravaud, P. (2006). Feeling good rather than feeling better matters more to patients. Arthritis Care and Research, 55(4), 526–530. doi:10.1002/art.22110.

    Article  PubMed  Google Scholar 

  37. Lang, A. E., Eberly, S., Goetz, C. G., Stebbins, G., Oakes, D., Marek, K., et al. (2013). Movement disorder society unified Parkinson disease rating scale experiences in daily living: Longitudinal changes and correlation with other assessments. Movement Disorders, 28(14), 1980–1986. doi:10.1002/mds.25671.

    Article  PubMed  Google Scholar 

  38. Middel, B., & van Sonderen, E. (2002). Statistical significant change versus relevant or important change in (quasi) experimental design: Some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. International Journal of Integrated Care, 2, e15.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by The Rosalyn Newman Foundation.

Author information

Authors and Affiliations

  1. Illinois Neurological Institute, University of Illinois College of Medicine-Peoria, 100 NE Randolph Avenue, Peoria, IL, 61606, USA

    Dronacharya Lamichhane

  2. Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA

    Ann L. Gruber-Baldini

  3. Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA

    Stephen G. Reich

  4. University of Maryland PD and Movement Disorders Center, University of Maryland School of Medicine, Baltimore, MD, USA

    Lisa M. Shulman

Authors
  1. Dronacharya Lamichhane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann L. Gruber-Baldini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen G. Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lisa M. Shulman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dronacharya Lamichhane.

Ethics declarations

Conflict of interest

Authors have no conflict of interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lamichhane, D., Gruber-Baldini, A.L., Reich, S.G. et al. Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson’s disease. Qual Life Res 25, 3139–3145 (2016). https://doi.org/10.1007/s11136-016-1351-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-016-1351-1

Keywords

Search

Navigation